Coherus Oncology, Inc. (CHRS)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
CHRS price, last 12 months
Key stats
- Previous close
- $0.4099
- Open
- $0.4045
- Day range
- $0.3701 – $0.4050
- 52-week range
- $0.3628 – $2.62
- Volume
- 4M
- Avg volume (20 days)
- 2.8M
- Market cap
- $81.2M
Performance
Technicals and fundamentals
About Coherus Oncology, Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $81.2M